[PERSON]
KEYNOTE‑B15/EV‑304
Featured in 1 tracked story · first seen
Situations
Pembrolizumab combo approvals and trial data
4 clusters · 10 sources · last updated
Latest: Enfortumab Vedotin‑Pembrolizumab Combo Boosts Survival in Muscle‑Invasive Bladder Cancer
Since mid‑2026 the FDA and the EU have authorized pembrolizumab in combination with the HIF‑2α inhibitor belzutifan for adjuvant treatment of high‑risk clear‑cell renal cell carcinoma, and with the antibody‑drug conjugat